



## COMPANY OVERVIEW

Oragenics, Inc. is focused on developing effective treatments for oral mucositis and becoming a leader in developing novel antibiotics against infectious diseases. Oragenics, Inc. has established exclusive worldwide channel collaborations with Precigen, Inc., a synthetic biology company. The collaborations allow Oragenics access to Precigen's proprietary technologies toward the goal of accelerating the development of much needed new antibiotics that can work against resistant strains of bacteria and new therapeutic probiotics designed to alleviate symptoms from oral diseases.

## RECENT NEWS

**Oragenics Announces Closing of \$6.0 Million Underwritten Public Offering**  
Nov 24 2020, 11:37 AM EST

## STOCK OVERVIEW

Symbol	OGEN
Exchange	NYSE American
Market Cap	23.55m
Last Price	\$0.386
52-Week Range	\$0.36 - \$2.09

11/24/2020 03:59 PM EST

## INVESTOR RELATIONS

CORE IR  
John Marco  
Managing Director  
T: 310-819-2948  
[johnm@coreir.com](mailto:johnm@coreir.com)

## MANAGEMENT TEAM

**Alan Joslyn, Ph.D.**  
President and Chief Executive Officer

**Michael Sullivan**  
Chief Financial Officer

**Dr. Martin Handfield**  
Senior Vice President of Discovery Research

## ORAGENICS, INC.

4902 Eisenhower Blvd.  
Suite 125  
Tampa, FL 33634  
US

## DISCLAIMER

Except for the historical information contained here in, the matters discussed in this document are forward-looking statements that involve risks and uncertainties, including but not limited to business conditions and the amount of growth in our industry and general economy, competitive factors, and other risks detailed from time to time in the Company's SEC reports, including but not limited to its annual reports on form 10-K and its quarterly reports on Form 10-Q. The company does not undertake any obligation to update forward-looking statements. All trademarks and brand name are the property of their respective companies.